Vol. 1 No. 2 (2015), ORIGINAL ARTICLES
Vol. 1 No. 2 (2015)

Clinical characteristics of paraguayan patients with established rheumatoid arthritis

ORIGINAL ARTICLES
Published 2015-12-30
Sonia Cabrera-Villalba
Universidad Nacional de Asunción, Facultad de Ciencias Médicas, Hospital de Clínicas, Departamento de Reumatología. San Lorenzo, Paraguay
Lourdes Román
Universidad Nacional de Asunción, Facultad de Ciencias Médicas, Hospital de Clínicas, Departamento de Reumatología. San Lorenzo, Paraguay
Yanira Yinde
Universidad Nacional de Asunción, Facultad de Ciencias Médicas, Hospital de Clínicas, Departamento de Reumatología. San Lorenzo, Paraguay
Aldo Ojeda
Universidad Nacional de Asunción, Facultad de Ciencias Médicas, Hospital de Clínicas, Departamento de Reumatología. San Lorenzo, Paraguay
Margarita Duarte
Universidad Nacional de Asunción, Facultad de Ciencias Médicas, Hospital de Clínicas, Departamento de Reumatología. San Lorenzo, Paraguay
PDF (Spanish)
HTML (Spanish)

Keywords

Rheumatoid Arthritis
Clinical Characteristics Epidemiological Characteristics

How to Cite

1.
Cabrera-Villalba S, Román L, Yinde Y, Ojeda A, Duarte M. Clinical characteristics of paraguayan patients with established rheumatoid arthritis. Rev. parag. reumatol. [Internet]. 2015 Dec. 30 [cited 2026 Jan. 16];1(2):94-8. Available from: https://revista.spr.org.py/index.php/spr/article/view/21
APA ABNT Harvard Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Introduction: Rheumatoid arthritis (RA) is a chronic rheumatic disease that can affect any joint but favors the small joints of the hands most often. The pattern of presentation and progression and other clinical features are unknown in the Paraguayan population. Objetive: The aim of the study was to know the clinical and epidemiological characteristics in the Paraguayan people with RA. Methods: Retrospective,descriptive study.Patients with diagnosis of RA with a follow-up in the Hospital de Clínicas-UNA Rheumatology Department.. Clinical, epidemiological, laboratorial variables were evaluated. Results: We included 82 patients (Female 84.1%), with a mean age of 53.4±11.9 years, diconocisease duration of 9.6±9 years. The most frequent pattern of joint involvement were oligo and polyarticular. 89.7% with positive ACPA. The patients with ACPA + had onset of disease more often symmetrically (CCP + 86.3% vsACPA(-) 57.1%, p 0.08), and had more erosive disease (ACPA+ 27.2% vs ACPA- 0%, p : 0.049) than the CCP negative patients. Conclusions: Paraguayan patients with established RA are mostly female, seropositive,with an oligo / polyarticular pattern joint involvement. The ACPA positive patients have a more symmetrical erosive disease.
PDF (Spanish)
HTML (Spanish)

References

(1) Klareskog L, Anca IC, Paget S. Rheumatoid Arthritis. Review. The L ancet. 2009;373:659–72.2. Spector TD. Rheumatoid arthritis. Rheum DisClin North Am. 1990;16(3):513-37.

(2) Spector TD. Rheumatoid arthritis. Rheum DisClin North Am. 1990;16(3):513-37.

(3) Cardiel MH, Rojas-Serrano J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol. 2002;20:617–24.

(4) Spindler A, Bellomio V, Berman A et al. Prevalence of rheumatoid arthritis in Tucuman, Argentina. J Rheumatol. 2002;29:1166-70.

(5) Carmona l, Villaverde V, Hernández-Garcia C, Ballina J, Gabriel R, Laffon A, et al. The prevalence of reumatoid arthritis in the general population of Spain. Rheumatology (Oxford). 2002;41(1):88-95.

(6) Massardo L, Suarez-Almazr ME, Cardiel MH, Nava A, Levy R, L aurindo I, et al. Management of patients with rheumatoid arthritis in Latin America. A consensus position paper from Pan-American League of Associations of Rheumatology and Grupo Latino Americano de studio de artritisreumatoide. J Clin Rheumatol. 2009;15:203-210.

(7) Ruiz-Esquide V, Sanmarti R. Tobacco and other environmental risk factors in rheumatoid arthritis. Reumatol Clin. 2012;8:342-50.

(8) Pincus T, Callahan LF. Quantitative measures to asses, monitor and predict morbidity and mortality in rheumatoid arthritis. Balliere‘s. Clin Rheumatol. 1992;6:161-91.

(9) Fürst DE. Predictors of worsening clinical variables and outcomes in rheumatoid arthritis. Rheum Dis Clin Worth Am. 1994;20:309-19.

(10) Willenze A, Trouw LA, Toes RE, Huizinga TW. The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol. 2012;8(3):144-52.

(11) Aletaha D,Neogi T,Silman AJ,Funovits J,FelsonDT,BinghamC, etal.2010 Rheumatoid arthritis classification criteria: An American College of Rheuma- tology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-81.

(12) Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford). 2000;39(1):24-9.

(13) Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum. 2003;48(7):1771-74.

(14) Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2006;20(5):849-63.

(15) Plant MJ, Jones PW, Saklatvala J, Ollier WE, Dawes PT. Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol.1998;25:417–26.

(16) Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, CooperNS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.

(17) Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35(4):745-57.

(18) Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol. 2003;30(1):167-78.

(19) Pincus T, Callahan LF. Formal education as a marker for incre ased mortality and morbidity in rheumatoid arthritis. J Chronic Dis. 1985;38(12):973-84.

(20) Massardo L, Pons-Estel BA, Wojdyla D, Cardiel MH, Galarza-Maldonado CM, Sacnun MP, et al.Early rheumatoid arthritis in Latin America: low socioeconomic status related to high disease activity at baseline. Arthritis Care Res. 2012;64(8):1135-43.

(21) Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2013 update. Ann RheumDis. 2014;73:492–509.

(22) T ornero Molina J, Ballina García FJ, Calvo Alén J, Caracuel Ruiz MA, Carbonell Abelló J, López Meseguer A, et al. Recommendations for the use of methotrexate in rheumatoid arthritis: Up and down scaling of the dose and administration routes. Reumatol Clin. 2015;11:3-8.

(23) T ornero Molina J, Sanmartí R, Rodríguez Valverde V, Martín Mola E, Marenco de la Fuente JL, González Álvaro I, et al. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. Reumatol Clin. 2010;6: 23-36.

(24) G rigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet. 2004;17-23:263-9.

(25) Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Utrecht Rheumatoid ArthritisCohort study group. Intensive treatment with methotrexate in early rheumatoid arthritis: Aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an openlabel strategy trial). Ann Rheum Dis. 2007;66:1443-9.

(26) Manuel F. Ugarte-Gil. Acces to an optimal treatment. Current situation. ClinRheumatol. 2015;34 (1):59-66.

(27) Al Maini M, Adelowo F, Al Saleh J, Al Weshahi Y, Burmester GR, Cutolo M, et al. The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases. ClinRheumatol. 2015;34(5):819-29.

(28) Ramagli A, Corbacho I, Linhares F, de Abreu P, Teijeiro R, G arau M, et al. Characteristics of Patients With Early-Onset Arthritis in Latin America: Description of the REPANARC Cohort. J Clin Rheumatol. 2015;21(6):283-8.

(29) Cardiel MH, Pons-Estel BA, Sacnun MP, Wojdyla D, Saurit V, Marcos JC, et al. Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience. J Clin Rheumatol. 2012;18(7):327-35.

Downloads

Download data is not yet available.